OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Cancer is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Subscription & copyright page	307
FBXW10: a male-biased E3 ligase in liver cancer	184
Engineering growth factor ligands and receptors for therapeutic innovation	179
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	173
Revumenib: a new era in acute leukemia treatment	170
Spliced to kill: RNA mis-splicing derived cancer neoantigens	166
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	157
Tumor-resident microbes: the new kids on the microenvironment block	148
Advisory Board and Contents	143
Subscription & copyright page	134
Subscription and copyright page	131
Navigating life as an early career researcher	130
Onco-condensates: formation, multi-component organization, and biological functions	129
Leveraging circulating microbial DNA for early cancer detection	126
Radiotherapy and immunotherapy: open questions and future strategies	126
Accessing the vasculature in cancer: revising an old hallmark	121
Engine shutdown: migrastatic strategies and prevention of metastases	115
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	115
Subscription & copyright page	112
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	112
GOT2 consider the tumor microenvironment	107
IDH-Mutant Brain Tumors Hit the Achilles’ Heel of Macrophages with R-2-Hydroxyglutarate	101
Crosstalk of T cells within the ovarian cancer microenvironment	88
Pannexin biology and emerging linkages to cancer	88
Chromosomal instability and aneuploidy as causes of cancer drug resistance	85

Advisory Board and Contents	81
Benefits and opportunities of the transgenic Oncopig cancer model	80
Recent developments in myeloid immune modulation in cancer therapy	75
Tumor immunology CRISPR screening: present, past, and future	73
Chromatin as an old and new anticancer target	72
Regulation of metastatic organotropism	71
Oncogenic competence: balancing mutations, cellular state, and microenvironment	67
Gut microbiota – a double-edged sword in cancer immunotherapy	66
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	65
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	65
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	63
Diet, nutrient supply, and tumor immune responses	63
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	62
Cell death, therapeutics, and the immune response in cancer	60
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	60
Subscription & copyright page	59
Subscription & copyright page	59
Advisory Board and Contents	58
Advisory Board and Contents	56
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	55
Palmitate paves the way to lung metastasis	55
Genetic immune escape in cancer: timing and implications for treatment	55
Clinical and translational relevance of intratumor heterogeneity	54
Scaling data toward pan-cancer foundation models	53
Advisory Board and Contents	53
Subscription & copyright page	52
β-Galactosylceramidase in cancer: friend or foe?	51